Uncategorized
Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report
Biopharma companies won’t fully capture the benefits of AI unless they reorganize their R&D units, according to McKinsey.
Biopharma companies won’t fully capture the benefits of AI unless they reorganize their R&D units, according to McKinsey.